Addition of venetoclax to azacitidine improves outcomes for subset of patients with AML

Treatment with venetoclax plus azacitidine conferred better outcomes than azacitidine alone among select patients with acute myeloid leukemia, according to study results presented at ASH Annual Meeting and Exposition.